SAB Biotherapeutics Inc - Warrants (25/07/2027)
SABSW
Get informed when a big investor buys or sells
+ FollowMarket Cap$38.23M
Close$
$0.07
642% upside
Current Fair Value
642% upsideUndervalued by 642% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $38.23 Million |
|---|---|
| Enterprise Value | $23.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.14 |
| Outstanding Shares | 53,558,639 |
Return
| Return on Equity | -0.18% |
|---|---|
| Return on Assets | -0.16% |
| Return on Invested Capital | -50.99% |
Valuation & Multiples
| P/E Ratio | -537.7 |
|---|---|
| PEG | -204.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 62,5000% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.20%▲ 1.62% |
|---|---|
| Total Invested | $21,061▲ 152.47% |
| Investors Holding | 7▼ 1.00% |
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.